Trial Profile
A double-blind, randomized, placebo-controlled study evaluating the efficacy of anti-IgE antibody, omalizumab, for the prevention of subsequent asthma exacerbations in children aged 6-12 years (OMALIZ612)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 26 Jul 2016 New trial record